Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00390091
Status:
WITHDRAWN
Last Update Posted:
2015-09-01
First Post:
2006-10-17
Brief Title:
Study of LJP 394 Abetimus Sodium in Lupus Patients
Sponsor:
La Jolla Pharmaceutical Company
Organization:
La Jolla Pharmaceutical Company
Study Overview
Official Title:
A Randomized Double-Blind Study to Evaluate the Safety Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus SLE
Status:
WITHDRAWN
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE
Detailed Description:
STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None